Merck's Vaccine Gardasil(TM) Will Be Best-Selling 2006-Approved Product, Forecasts URCH Report: New Publication Finds That 11 of the 40 New Drugs Given First Approval in 2006 Are Tipped to Be Able to Generate Peak Annual Sales in Excess of US$500 Million

Share Article

TODAY, URCH Publishing Ltd (http://www.urchpublishing.com), a leading independent provider of information to the pharmaceutical industry, announces the availability of a unique report assessing the trends evident globally in approving new pharmaceutical products.

The leading companies by current and prospective new pharmaceutical product approvals this year are GSK, Wyeth and Novartis with four potential approvals each.

    Pharmaceutical Product Approval Trends 2007 - Key market benchmarks and strategic insights finds that among the 40 new pharmaceutical products given first approval in 2006, 11 new drugs are considered to have the potential to generate peak annual sales in excess of US$500 million.

The leading 2006 approved product by forecast sales in 2011 is Merck's Gardasil/ Silgard which is a human papillomavirus vaccine. Gardasil is forecast to surpass sales of US$3 billion in 2011. Among the other drugs predicted to reach peak global sales higher than US$500 million are Novartis' anti-hypertensive Exforge(TM), Johnson and Johnson's protease inhibitor Prezista(TM), Sanofi-Aventis' appetite suppressant Acomplia(TM) (rimonabant), and smoking-cessation aid Chantix(TM) (varenicline).

The study says that the leading companies by number of new drug approvals with significant market potential in 2006 were Pfizer, J&J, Merck and Novartis with two.

Gardasil/ Silgard (human papillomavirus vaccine) is a recombinant vaccine indicated for the prevention of cervical cancer caused by human papillomavirus (HPV) and first received approval in the US in June 2006 before receiving EU approval in September 2006. It generated global sales of US$235 million in 2006.

Steven Seget, author of the report from URCH, commenting on the changes that have taken place in 2007, said, "The leading companies by current and prospective new pharmaceutical product approvals this year are GSK, Wyeth and Novartis with four potential approvals each." He notes that smaller companies are forecast to generate a high share of new drug approvals in 2007, including Shire with three and Cephalon with two.

For more information about Pharmaceutical Product Approval Trends 2007

http://www.urchpublishing.com/publications/sales/pharma_product_ap proval.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

URCH Publishing is an independent business information publisher dedicated to delivering high quality information products to the global pharmaceuticals industry.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Edwin Bailey
URCH Publishing
+44 (0)207 060 1099
Email >
Visit website